Outcomes for women receiving long-acting cabotegravir plus rilpivirine monthly and every two months: ATLAS-2M study Week 48 results

被引：0
|
作者：
Benn, P. [1 ]
Quercia, R. [2 ]
Hudson, K. [3 ]
Wang, Y. [4 ]
Chounta, V. [5 ]
Talarico, C. [6 ]
Ford, S. [7 ]
Cutrell, A. [8 ]
Margolis, D. [9 ]
Van Solingen-Ristea, R. [10 ]
Vanveggel, S. [10 ]
Van Eygen, V. [10 ]
Polli, J. [11 ]
de Ruiter, A. [11 ]
Smith, K. [12 ]
Spreen, W. [9 ]
机构：
[1] ViiV Healthcare, Clin Dev, Brentford, England
[2] ViiV Healthcare, Clin Virol, Brentford, England
[3] ViiV Healthcare, Clin Dev, Res Triangle Pk, NC USA
[4] GlaxoSmithKline, Stat, R&D, Collegeville, PA USA
[5] ViiV Healthcare, Global Hlth Outcomes, Brentford, England
[6] ViiV Healthcare, Translat Med Res, Res Triangle Pk, NC USA
[7] GlaxoSmithKline, Clin Pharmacol Modelling & Simulat, Res Triangle Pk, NC USA
[8] ViiV Healthcare, Stat, R&D, Res Triangle Pk, NC USA
[9] ViiV Healthcare, Clin Dev, R&D, Res Triangle Pk, NC USA
[10] Janssen Res & Dev, Clin R&D, Beerse, Belgium
[11] ViiV Healthcare, Global Med Sci, Res Triangle Pk, NC USA
[12] ViiV Healthcare, R&D, Res Triangle Pk, NC USA
来源：
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
P017
引用
收藏
页码：28 / 29
页数：2
相关论文
共 50 条
  • [41] Implementation of cabotegravir and rilpivirine long-acting (CAB plus RPV LA): primary results from the CAB plus RPV Implementation Study in European Locations (CARISEL)
    Van Welzen, B.
    Vandekerckhove, L.
    Jonsson-Oldenbuettel, C.
    Hocqueloux, L.
    Ait-Khaled, M.
    Bontempo, G.
    DeMoor, R.
    Scherzer, J.
    D'Amico, R.
    Barnes, N.
    Hadi, M.
    Low, E.
    Anand, S.
    Czarnogorski, M.
    Gutner, C.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 71 - 72
  • [42] Results at month 7 of CABO-CHANCE study: real-world evidence (RWE) on the use of intramuscular cabotegravir plus rilpivirine long-acting (CAB plus RPV LA) dosed every 2 months in viral suppressed people with HIV (PWH)
    Tenorio, Carmen Hidalgo
    Aguilera-Garcia, Maria
    Santos, Ignacio De Los
    Vinuesa, David
    Omar, Mohamed
    Lirola, Ana Lopez
    Bernal, Enrique
    Martinez, Onofre Juan
    Romero, Alberto
    Sorni, Patricia
    Lopez, Teresa
    Cardenas, Salvador Lopez
    Moreno, Santiago
    Conde, Isabel San Joaquin
    Blanco, Jose Ramon
    Garcia-Vallecillos, Coral
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 108 - 109
  • [43] Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study
    Orkin, Chloe
    Oka, Shinichi
    Philibert, Patrick
    Brinson, Cynthia
    Bassa, Ayesha
    Gusev, Denis
    Degen, Olaf
    Garcia, Juan Gonzalez
    Morell, Enrique Bernal
    Tan, Darrell H. S.
    D'Amico, Ronald
    Dorey, David
    Griffith, Sandy
    Thiagarajah, Shanker
    St Clair, Marty
    Van Solingen-Ristea, Rodica
    Crauwels, Herta
    Ford, Susan L.
    Patel, Parul
    Chounta, Vasiliki
    Vanveggel, Simon
    Cutrell, Amy
    Van Eygen, Veerle
    Vandermeulen, Kati
    Margolis, David A.
    Smith, Kimberly Y.
    Spreen, William R.
    LANCET HIV, 2021, 8 (04): : e185 - e196
  • [44] Patient-reported tolerability and acceptability of cabotegravir plus rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 study
    Murray, Miranda
    Pulido, Federico
    Mills, Anthony
    Ramgopal, Moti
    LeBlanc, Roger
    Jaeger, Hans
    Canon, Viviam
    Dorey, David
    Griffith, Sandy
    Mrus, Joseph
    Spreen, William
    Margolis, David
    HIV RESEARCH & CLINICAL PRACTICE, 2019, 20 (4-5) : 111 - 122
  • [45] Thigh Injections of Cabotegravir plus Rilpivirine in Virally Suppressed Adults With Human Immunodeficiency Virus Type 1: A Substudy of the Phase 3b ATLAS-2M Study
    Ford, Susan L.
    Felizarta, Franco
    Han, Kelong
    Wang, Kehui
    Crauwels, Herta
    Dari, Anna
    Masia, Mar
    Deltoro, Miguel Garcia
    Degen, Olaf
    Angel, Jonathan B.
    Hsiao, Chiu-Bin
    Acuipil, Carolina
    Kolobova, Irina
    Harrington, Conn
    Rimler, Kelly
    Spreen, William
    D'Amico, Ronald
    CLINICAL INFECTIOUS DISEASES, 2025,
  • [46] Six-month outcomes of every 2-months long-acting cabotegravir and rilpivirine in a real-world setting: effectiveness, adherence to injections and patient-reported outcomes from PLWHIV in the German CARLOS cohort
    Borch, J.
    Scherzer, J.
    Jonsson-Oldenbuettel, C.
    Weinberg, G.
    Wyen, C.
    Rodriguez, E.
    Scholten, S.
    Dakhia, S.
    Dymek, K.
    Westermayer, B.
    Bernhardt, K.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 20 - 21
  • [47] Perspectives of People With Human Immunodeficiency Virus on Implementing Long-acting Cabotegravir Plus Rilpivirine in Clinics and Community Settings in the United Kingdom: Results From the Antisexist, Antiracist, Antiageist Implementing Long-acting Novel Antiretrovirals Study
    Orkin, Chloe
    Hayes, Rosalie
    Haviland, Joanne
    Wong, Yuk Lam
    Ring, Kyle
    Apea, Vanessa
    Kasadha, Bakita
    Clarke, Emily
    Byrne, Ruth
    Fox, Julie
    Barber, Tristan J.
    Clarke, Amanda
    Paparini, Sara
    ILANA study Grp, Sadna
    CLINICAL INFECTIOUS DISEASES, 2025,
  • [48] Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial
    Kityo, Cissy
    Mambule, Ivan K.
    Musaazi, Joseph
    Sokhela, Simiso
    Mugerwa, Henry
    Ategeka, Gilbert
    Cresswell, Fiona
    Siika, Abraham
    Kosgei, Josphat
    Shah, Reena
    Naidoo, Logashvari
    Opiyo, Kimton
    Otike, Caroline
    Moller, Karlien
    Kaimal, Arvind
    Wambui, Charity
    Van Eygen, Veerle
    Mohammed, Perry
    Boateng, Fafa Addo
    Paton, Nicholas, I
    LANCET INFECTIOUS DISEASES, 2024, 24 (10): : 1083 - 1092
  • [49] Improvements in Patient-Reported Outcomes After 12 Months of Maintenance Therapy With Cabotegravir plus Rilpivirine Long-Acting Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide in the Phase 3b SOLAR Study
    Mussini, Cristina
    Cazanave, Charles
    Adachi, Eisuke
    Eu, Beng
    Alonso, Marta Montero
    Crofoot, Gordon
    Chounta, Vasiliki
    Kolobova, Irina
    Sutton, Kenneth
    Sutherland-Phillips, Denise
    Urbaityte, Rimgaile
    Ehmann, Alice
    Scherzer, Jenny
    de los Rios, Patricia
    D'Amico, Ronald
    Spreen, William
    van Wyk, Jean
    AIDS AND BEHAVIOR, 2025, 29 (01) : 64 - 76
  • [50] Week 124 results of the randomized, open-label, Phase 3 FLAIR study evaluating long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection (ITT-E population)
    Orkin, C.
    D'Amico, R.
    Bernal Morell, E.
    Tan, D. H. S.
    Katner, H.
    Singh, Y.
    Stellbrink, H-J
    Belonosova, E.
    DeMoor, R.
    Griffith, S.
    Thiagarajah, S.
    Van Solingen-Ristea, R.
    Ford, S. L.
    Crauwels, H.
    Patel, P.
    Cutrell, A.
    Smith, K. Y.
    Vandermeulen, K.
    St Clair, M.
    Spreen, W. R.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2021, 24 : 22 - 22
12345